Shanghai Junshi Bioscience Co., Ltd.

This study tests whether adding the immunotherapy drug toripalimab to the standard targeted therapy lenvatinib helps people with advanced liver cancer live longer. About 530 adults with liver cancer that cannot be treated with surgery will receive either the combination or a plac…

This early-phase study tests a new drug called JS203 in about 104 adults with B-cell non-Hodgkin's lymphoma that has come back or not responded to treatment. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participants will re…

This study tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before and after surgery helps people with a certain type of advanced esophageal cancer live longer without the cancer coming back. About 663 participants will receive either the drug com…

This early-stage study tests a new drug, JS207, in about 98 adults with advanced solid tumors that have not responded to standard treatments or have no standard therapy. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Research…